Visceral fat: A key mediator of steatohepatitis in metabolic liver disease

Hepatology

Volumn 48, Issue 2, 2008, Pages 449-457

  van der Poorten, David ^a   Milner, Kerry Lee ^b   Hui, Jason ^b   Hodge, Alexander ^a   Trenell, Michael I ^c   Kench, James G ^d   London, Roslyn ^a   Peduto, Tony ^d   Chisholm, Donald J ^b   George, Jacob ^a,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; CHOLESTEROL; GLUCOSE; INSULIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ABDOMINAL FAT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCAR FORMATION; TRIACYLGLYCEROL BLOOD LEVEL;

ABDOMEN; ADULT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HEPATITIS; HUMANS; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SUBCUTANEOUS FAT;

EID: 49649096375     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22350     Document Type: Article

References (36)

1. Vague J. The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr 1956;4:20-34.
2. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: A new worldwide definition. Lancet 2005;366:1059-1062.
3. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Scatemem. Circulation 2005;112:2735-2752.
4. Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) 2006;14:336-341.
5. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-887.
6. Després J. Inflammation and cardiovascular disease: Is abdominal obesity the missing link? Int J Obes 2003;27(Suppl 3):S22-S24.
7. Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogary P, Nadeau A, et al. Elevated C-reactive protein: Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21:961-967.
8. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998;280:1843-1848.
9. Marchesini G, Brizi M, Bianchi G, Tomassctti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.
10. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
11. Rasband W, U.S. National Institutes of Health. ImageJ 1.40 [computer program]. Available at: Http://rsb.info.nih.gov/ij/; 1997-2007.
12. Petersen KF, West AB, Reuben A, Rothman DL, Shulman GI. Noninvasive assessment of hepatic triglyccride content in humans with 13C nuclear magnetic resonance spectroscopy. HEPATOLOGY 1996;24:114-117.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
14. Positano V, Gastaldelli A, Sironi AM, Santarelli MF, Lombardi M, Landini L. An accurate and robust method for unsupervised assessment of abdominal fat by MRI. J Magn Reson Imaging 2004;20:684-689.
15. Snyder W, Cooke M, Mnassett E, Larhansen L, Howells G, Tipton I. Report of the Task Group on Reference Man, Oxford, UK: Pergamon; 1975.
16. Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD, Kabir M, et al. Why visceral fat is bad: Mechanisms of the metabolic syndrome. Obesity (Silver Spring) 2006;14(Suppl 1):16S-19S.
17. Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci 2003;24:276-283.
18. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-152.
19. Chan DC, Watts GF, Ng TW, Hua J, Song S, Barrett PH. Measurement of liver fat by magnetic resonance imaging: Relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes Obes Metab 2006;8:698-702.
20. Thomas EL, Hamilton G, Patel N, O'Dwyer R, Dore CJ, Goldin RD, et al. Hepatic triglyceride content and its relation to body adiposity: A magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005;54:122-127.
21. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830.
22. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): Implication of macrophages resident in the AT. J Clin Endocrinol Metab 2005;90:2282-2289.
23. Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men: Role of visceral adipose tissue. Diabetes Med 2005;22:1354-1358.
24. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? HEPATOLOGY 2004;40:46-54.
25. Fenkci S, Rota S, Sabir N, Sermez Y, Guclu A, Akdag B. Relationship of serum interleukin-6 and tumor necrosis factor alpha levels with abdominal fat distribution evaluated by ultrasonography in overweight or obese post-menopausal women. J Invest Med 2006;54:455-460.
26. Diamant M, Lamb HJ, van de Ree MA, Endert EL, Groeneveld Y, Bots ML, et al. The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes. J Clin Endocrinol Metab 2005;90:1495-1501.
27. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/ adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003;278:9073-9085.
28. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 2004;219:9-15.
29. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307.
30. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-2791.
31. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-89.
32. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-1737.
33. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: The plot thickens. Diabet Med 2007;24: 1-6.
34. Targher G, Bertolini L, Padovani R, Poli F, Scala L, Tessari R, et al. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 2006;23:403-409.
35. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study. Lancet 2005;366: 1640-1649.
36. Empana JP, Ducimetiere P, Charles MA, Jouven X. Sagittal abdominal diameter and risk of sudden death in asymptomatic middle-aged men: The Paris Prospective Study I. Circulation 2004;110:2781-2785.